Lumos Financial Statements From 2010 to 2025
| LDXHF Stock | USD 0.19 0.01 5.56% |
Check Lumos Diagnostics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Lumos Diagnostics' main balance sheet or income statement drivers, such as , as well as many indicators such as . Lumos financial statements analysis is a perfect complement when working with Lumos Diagnostics Valuation or Volatility modules.
Lumos |
Lumos Diagnostics Holdings Company Return On Asset Analysis
Lumos Diagnostics' Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
Current Lumos Diagnostics Return On Asset | -0.25 |
Most of Lumos Diagnostics' fundamental indicators, such as Return On Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Lumos Diagnostics Holdings is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.
| Competition |
Based on the latest financial disclosure, Lumos Diagnostics Holdings has a Return On Asset of -0.2491. This is 97.15% lower than that of the Healthcare sector and 96.69% lower than that of the Diagnostics & Research industry. The return on asset for all United States stocks is 77.93% higher than that of the company.
Lumos Diagnostics Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Lumos Diagnostics's current stock value. Our valuation model uses many indicators to compare Lumos Diagnostics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Lumos Diagnostics competition to find correlations between indicators driving Lumos Diagnostics's intrinsic value. More Info.Lumos Diagnostics Holdings is currently regarded as number one stock in return on equity category among its peers. It also is currently regarded as number one stock in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Lumos Diagnostics' earnings, one of the primary drivers of an investment's value.About Lumos Diagnostics Financial Statements
Lumos Diagnostics stakeholders use historical fundamental indicators, such as Lumos Diagnostics' revenue or net income, to determine how well the company is positioned to perform in the future. Although Lumos Diagnostics investors may analyze each financial statement separately, they are all interrelated. For example, changes in Lumos Diagnostics' assets and liabilities are reflected in the revenues and expenses on Lumos Diagnostics' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Lumos Diagnostics Holdings. Please read more on our technical analysis and fundamental analysis pages.
Lumos Diagnostics Holdings Limited, a contract research and development company, develops and commercializes rapid point-of-care diagnostic tests which are primarily focuses on the diagnosis and management of infectious diseases in the United States and Australia. Lumos Diagnostics Holdings Limited was founded in 2004 and is based in Melbourne, Australia. Lumos Diagnostics operates under Diagnostics Research classification in the United States and is traded on OTC Exchange.
Currently Active Assets on Macroaxis
| DD | Dupont De Nemours | |
| CRDO | Credo Technology Group | |
| GOOG | Alphabet Inc Class C | |
| BAC | Bank of America | |
| CRM | Salesforce |
Other Information on Investing in Lumos Pink Sheet
Lumos Diagnostics financial ratios help investors to determine whether Lumos Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Lumos with respect to the benefits of owning Lumos Diagnostics security.